Not Hedging. Not Performing.
Dr. Tracy Beth Høeg and the science behind the Plausible Mechanism Pathway
I did not go to the HHS Press Conference on the Plausible Mechanism Pathway expecting to have my thinking changed. I went because I follow this agency closely, and I believe in where it is headed.
I left differently.
The Plausible Mechanism Pathway, or PMP, is a new FDA approval approach built for ultra-rare diseases, conditions so uncommon that enrolling enough patients for a traditional randomized controlled trial is simply not feasible. For the families living with these diseases, the old framework was not just slow. It was a wall.
The usual elected officials were there. The room had the familiar feel of prepared remarks and careful language. But somewhere in the middle of it all, Tracy Beth Høeg, M.D., Ph.D., the Acting Director of the Center for Drug Evaluation and Research, started speaking. She was not hedging. She was not performing. She was making a scientific argument, and making it plainly. And something shifted for me.
Høeg is exactly the kind of voice the moment calls for. She joined the FDA in March 2025 as a Special Assistant before becoming Senior Advisor for Clinical Sciences to Commissioner Makary, bringing with her deep work in areas like animal testing alternatives and computational modeling of drug safety and efficacy. None of it is abstract. Her work represents a vision of healthcare that is more patient-centered, more market-responsive, and more honest about what the evidence can and cannot tell us.
She made the case plainly: a single trial conducted under the PMP could generate evidence strong enough to support therapies across multiple diseases that share the same underlying molecular mechanism.
Not one disease unlocked at a time. Many at once.
I had to sit with that for a moment.
Somewhere right now, there is a parent who has been told there is nothing in the pipeline for their child. A patient who has aged out of hope. For people like them, a shift like the PMP is not a regulatory detail. For them, it is everything.
What Høeg is bringing to the FDA is rarer than most people realize. Scientific rigor and genuine innovation do not always arrive in the same person, at the same time, with the authority to act on both. In her, they have. The Plausible Mechanism Pathway did not happen by accident. It happened because someone who understands the science deeply enough to challenge old assumptions was in the room where the decisions get made. Healthcare innovation in America has a new center of gravity, and Høeg is helping build it.
Dr. Høeg is an example of when science and purpose move in the same direction. I cannot wait to see what comes next.
Views are my own.